Filing Flows › Comparisons › ALNY vs JAZZ
Alnylam Pharmaceuticals vs Jazz Pharmaceuticals: ALNY and JAZZ compared
Alnylam Pharmaceuticals is the larger company: $1.5B of revenue in its latest quarter (Q3 2026) against $1.2B for Jazz Pharmaceuticals (Q3 2026). Alnylam Pharmaceuticals is growing faster (+17% against +10% a year earlier). Alnylam Pharmaceuticals is more profitable, with an operating margin of 23.7% against -33.3%.
Where the money goes: ALNY and JAZZ
Alnylam Pharmaceuticals (ALNY) · Q3 2026
Alnylam Pharmaceuticals, Q3 2026: revenue $1.5B (+17% year over year), operating margin 23.7%, net earnings $2.2B, operating cash flow $341M. The chart follows the revenue to costs, profit and cash.
Jazz Pharmaceuticals (JAZZ) · Q3 2026
Jazz Pharmaceuticals, Q3 2026: revenue $1.2B (+10% year over year), operating margin -33.3%, net loss $483M, operating cash flow $506M. The chart follows the revenue to costs, profit and cash.
| Alnylam Pharmaceuticals (ALNY) | Jazz Pharmaceuticals (JAZZ) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $1.5B | $1.2B |
| Revenue growth, Y/Y | +17% | +10% |
| Operating margin | 23.7% | -33.3% |
| Net earnings | $2.2B | −$483M |
| Net margin | 148.6% | -38.9% |
| Operating cash flow | $341M | $506M |
| Free cash flow | $271M | $490M |
| Market value | $21.6B | $15.2B |
| P/E | 8.0× | 76.5× |
| Analysts’ mean target | $302.48 | $296.27 |
Where the revenue comes from
Alnylam Pharmaceuticals
- Net product revenues: $1.3B (89%)
- Total Rare: $142M (10%)
- ONPATTRO: $19.6M (1%)
Jazz Pharmaceuticals
- Sleep: $514M (41%)
- Xywav: $482M (39%)
- Rylaze/Enrylaze: $106M (9%)
- Zepzelca: $104M (8%)
Questions
Which is bigger, Alnylam Pharmaceuticals or Jazz Pharmaceuticals?
Alnylam Pharmaceuticals is the larger company: $1.5B of revenue in its latest quarter (Q3 2026) against $1.2B for Jazz Pharmaceuticals (Q3 2026).
Is Alnylam Pharmaceuticals or Jazz Pharmaceuticals growing faster?
Alnylam Pharmaceuticals is growing faster (+17% against +10% a year earlier).
Which is more profitable, Alnylam Pharmaceuticals or Jazz Pharmaceuticals?
Alnylam Pharmaceuticals is more profitable, with an operating margin of 23.7% against -33.3%.
More: Alnylam Pharmaceuticals earnings · how Alnylam Pharmaceuticals makes money · Jazz Pharmaceuticals earnings · how Jazz Pharmaceuticals makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Oct 29, 2026; 10-Q filed Nov 2, 2026). Fiscal quarters can end on different dates. Not investment advice.